Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 8/20 | 0.74 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.74 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | IGF2R | P11717 | 2/20 | 0.48 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.45 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SIGLEC7 | Q9Y286 | 2/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21852877 | 1.00 | LGALS3 (0.74) | LGALS3LGALS8LGALS4MAPK1IGF2R | |
| SCHEMBL21258434 | 1.00 | LGALS3 (0.74) | LGALS3LGALS8LGALS4MAPK1IGF2R | |
| SCHEMBL17252078 | 1.00 | LGALS3 (0.74) | LGALS3LGALS8LGALS4MAPK1IGF2R | |
| SCHEMBL19197226 | 1.00 | LGALS3 (0.74) | LGALS3LGALS8LGALS4MAPK1IGF2R | |
| SCHEMBL21258435 | 1.00 | LGALS3 (0.74) | LGALS3LGALS8LGALS4MAPK1IGF2R | |
| SCHEMBL19196654 | 1.00 | LGALS3 (0.74) | LGALS3LGALS8LGALS4MAPK1IGF2R | |
| SCHEMBL21851468 | 0.96 | LGALS3 (0.68) | LGALS3LGALS8LGALS4MAPK1IGF2R | |
| SCHEMBL19197194 | 0.96 | LGALS3 (0.68) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL19567579 | 0.96 | LGALS3 (0.68) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL21851348 | 0.93 | LGALS3 (0.64) | LGALS3LGALS8LGALS4MAPK1IGF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766483-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | KODE BIOTECH LIMITED (NZ) | 2023-09-19 | — | — | US | disclosed |
| US-20180057518-A1 | SYNTHETIC MEMBRANE ANCHORS | KODE BIOTECH LTD. (NZ) | 2018-03-01 | — | — | US | disclosed |
| US-20170320914-A1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | BOVIN NICOLAI VLADIMIROVICH (RU) | 2017-11-09 | — | — | US | disclosed |
| US-20170266214-A1 | GLYCOLIPID CONTAINING COMPOSITIONS FOR USE IN THE TREATMENT OF TUMOURS | KREOS CAPITAL V (EXPERT FUND) L.P. (JE) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | SGMS1, SGMS2, CERT1 | LGALS3 2038/4885LGALS8 2012/4885LGALS4 2425/4885 |
| US-20180057518-A1 | SYNTHETIC MEMBRANE ANCHORS | PTDSS2, DDOST, STT3B | LGALS3 429/4885LGALS8 541/4885LGALS4 253/4885 |
| US-11766483-B2 | Compounds and therapeutics uses thereof | MAVS, MYD88, CD47 | LGALS3 139/4885LGALS8 156/4885LGALS4 107/4885 |
| US-20170266214-A1 | GLYCOLIPID CONTAINING COMPOSITIONS FOR USE IN THE TREATMENT OF TUMOURS | LGALS2, LGALS3, LGALS1 | LGALS3 2/4885LGALS8 7/4885LGALS4 5/4885 |
| US-20170320914-A1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | PHOSPHO1, MGLL, LPAR6 | LGALS3 474/4885LGALS8 564/4885LGALS4 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.